BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

MentiNova

MentiNova logo

Founded
2013
Geography
United States of America based
Funding
$0.500 M

MentiNova’s primary strategy is to use L-DOPA, the drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson’s disease.

Technologies

Pharmaceutical and Drug Discovery  

R&D Platform


Pipelines

No pipelines published yet

Products

 

Services

No services posted yet